AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30663977 — intervention group
Group type: EXPERIMENTAL
Intervention: IBI305
Number of subjects: 100
Study 30136447 — intervention group
Group type: EXPERIMENTAL
Intervention: linaclotide 0.5 mg
Number of subjects: 500
Study 30136447 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 500
Study 30136447 — intervention group
Group type: EXPERIMENTAL
Intervention: linaclotide (after switching from placebo)
Number of subjects: 500
Study 27737713 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management plan with a temporary quadrupling of the dose of inhaled corticosteroid (maximum of 14 days)
Number of subjects: 1800
Study 27737713 — intervention group
Group type: COMPARATOR
Intervention: Self-management plan without an increase in inhaled corticosteroid
Number of subjects: 1800
Study 24588434 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity CRRT (25 mL/kg/hour)
Number of subjects: 1441
Study 24588434 — intervention group
Group type: COMPARATOR
Intervention: High-intensity CRRT (40 mL/kg/hour)
Number of subjects: 1441
Study 21974692 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary prevention programme (IG)
Number of subjects: 102
Study 21974692 — intervention group
Group type: COMPARATOR
Intervention: Medically treated by local dermatologists (CG)
Number of subjects: 102
Study 20090434 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled dosing of acetaminophen and hydrocodone (167 mg/2.5 mg/5 mL) every 4 hours ATC (Groups B and C)
Number of subjects: 113
Study 20090434 — intervention group
Group type: COMPARATOR
Intervention: PRN dosing of acetaminophen and hydrocodone every 4 hours (Group A)
Number of subjects: 113
Study 20090434 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled dosing of acetaminophen and hydrocodone (167 mg/2.5 mg/5 mL)
Number of subjects: 113
Study 17526976 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (5 mg tid)
Number of subjects: 232
Study 17526976 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide mononitrate (ISMN: 20 mg bid)
Number of subjects: 232
Study 17526976 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil and ISMN
Number of subjects: 232
Study 17526976 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 232
Study 15476906 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 40 mg/d
Number of subjects: 293
Study 15476906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 293
Study 11522870 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation (12 g/day)
Number of subjects: 28
Study 11522870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 9760009 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (40 mg)
Number of subjects: 0
Study 9760009 — intervention group
Group type: COMPARATOR
Intervention: Captopril (25 mg)
Number of subjects: 0
Study 9760009 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (80 mg)
Number of subjects: 0
Study 8156094 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy for 3 years
Number of subjects: 10
Study 3045718 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose gentamicin therapy (n = 39)
Number of subjects: 69
Study 3045718 — intervention group
Group type: COMPARATOR
Intervention: Seven day course of an appropriate antibiotic (n = 30)
Number of subjects: 69
Study 3045718 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose gentamicin therapy
Number of subjects: 69
Study 3045718 — intervention group
Group type: COMPARATOR
Intervention: Seven day course of an appropriate antibiotic
Number of subjects: 69
Study 31852385 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion meditation
Number of subjects: 74
Study 31852385 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness meditation
Number of subjects: 74
Study 31852385 — intervention group
Group type: COMPARATOR
Intervention: Active control class
Number of subjects: 74
Study 31852385 — intervention group
Group type: COMPARATOR
Intervention: No-class control
Number of subjects: 74
Study 29766259 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone outcall program
Number of subjects: 108
Study 27662042 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular human insulin by jet injection (0.2 units/kg)
Number of subjects: 20
Study 27662042 — intervention group
Group type: COMPARATOR
Intervention: Insulin aspart by conventional pen
Number of subjects: 20
Study 24895108 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium (UMEC) 62.5 mcg QD
Number of subjects: 2
Study 24895108 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium (UMEC) 125 mcg QD
Number of subjects: 2
Study 24895108 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium (UMEC) doses ≥62.5 mcg QD
Number of subjects: 2
Study 24895108 — intervention group
Group type: COMPARATOR
Intervention: Umeclidinium (UMEC) BID dosing
Number of subjects: 2
Study 24895108 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium (UMEC) QD dosing
Number of subjects: 2
Study 23165811 — intervention group
Group type: COMPARATOR
Intervention: Normal group (hemoglobin concentration 12-15 g/dl), n=42
Number of subjects: 86
Study 23165811 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemic group (hemoglobin concentration 7-10 g/dl), n=44
Number of subjects: 86
Study 23165811 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemic group (hemoglobin concentration 7-10 g/dl)
Number of subjects: 86
Study 23165811 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 86
Study 20977018 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentors (fifth-year students)
Number of subjects: 0
Study 20977018 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentees (fourth-year students)
Number of subjects: 0
Study 20977018 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-mentors)
Number of subjects: 0
Study 20977018 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-mentees)
Number of subjects: 0
Study 18414916 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg morphine
Number of subjects: 60
Study 18414916 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg morphine
Number of subjects: 60
Study 18414916 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg morphine
Number of subjects: 60
Study 18414916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15740945 — intervention group
Group type: EXPERIMENTAL
Intervention: Redivac drains
Number of subjects: 546
Study 15740945 — intervention group
Group type: COMPARATOR
Intervention: Conventional underwater-seal drains
Number of subjects: 546
Study 12433017 — intervention group
Group type: EXPERIMENTAL
Intervention: Action letters (messages providing information on where and when to receive a flu shot)
Number of subjects: 0
Study 12433017 — intervention group
Group type: COMPARATOR
Intervention: No letters (no messages)
Number of subjects: 0
Study 12433017 — intervention group
Group type: COMPARATOR
Intervention: Reminder letters (messages intended to increase flu immunizations)
Number of subjects: 0
Study 10378673 — intervention group
Group type: COMPARATOR
Intervention: Constant rate infusion of HAI FUDR (80 mg/m2/day) and i.v. 5-FU (1200 mg/m2/day) for 5 days every 3 weeks (schedule A)
Number of subjects: 56
Study 10378673 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronotherapy with sinusoidal modulation of HAI FUDR (80 mg/m2/day) and i.v. 5-FU (1200 mg/m2/day) for 5 days every 3 weeks (schedule B)
Number of subjects: 56
Study 10378673 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule B (Chronotherapy)
Number of subjects: 56
Study 10378673 — intervention group
Group type: COMPARATOR
Intervention: Schedule A (Constant rate infusion)
Number of subjects: 56
Study 8907090 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical Bayes methods based on a random‐effects regression model
Number of subjects: 0
Study 1986037 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamin supplementation (10 mg daily)
Number of subjects: 80
Study 1986037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 6688635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (650 mg)
Number of subjects: 26
Study 6688635 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetaminophen elixir (650 mg)
Number of subjects: 26
Study 6688635 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetaminophen tablet (650 mg)
Number of subjects: 26
Study 6688635 — intervention group
Group type: COMPARATOR
Intervention: Two commercially available tablet formulations (325 mg each)
Number of subjects: 26
Study 30380332 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric disclosure
Number of subjects: 35
Study 30380332 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitators and barriers of disclosure
Number of subjects: 35
Study 27477485 — intervention group
Group type: EXPERIMENTAL
Intervention: scFOS (5 g d-1) for 4 weeks
Number of subjects: 79
Study 27477485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 27477485 — intervention group
Group type: EXPERIMENTAL
Intervention: scFOS
Number of subjects: 79
Study 25615566 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 76
Study 25615566 — intervention group
Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 76
Study 25615566 — intervention group
Group type: COMPARATOR
Intervention: Combination treatment
Number of subjects: 76
Study 25015368 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 0
Study 25015368 — intervention group
Group type: COMPARATOR
Intervention: Befriending (active comparison condition)
Number of subjects: 0
Study 22522141 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg/day with probiotics (Enterococcus faecalis JPC 30 million, Clostridium butyricum 2 million, Bacillus mesentericus JPC 1 million, Bacillus coagulans 50 million spores) at a dose of two capsules three times daily (group 1)
Number of subjects: 110
Study 22522141 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin with placebo (group 2)
Number of subjects: 110
Study 22522141 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg/day with probiotics (group 1)
Number of subjects: 110
Study 21141289 — intervention group
Group type: EXPERIMENTAL
Intervention: Chart Card
Number of subjects: 94
Study 21141289 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 94
Study 17590511 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg levodopa/50 mg benserazide during endurance exercise
Number of subjects: 20
Study 17590511 — intervention group
Group type: COMPARATOR
Intervention: 200 mg levodopa/50 mg benserazide during rest
Number of subjects: 20
Study 16304854 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel Lowplat (drug B) 600 mg (8 tablets) given once
Number of subjects: 0
Study 16304854 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel Plavix (drug A) 600 mg (8 tablets) given once
Number of subjects: 0
Study 11943134 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 600 mg during fasting and 1 g postprandially
Number of subjects: 23
Study 11943134 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 23
Study 11943134 — intervention group
Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 23
Study 11943134 — intervention group
Group type: EXPERIMENTAL
Intervention: 12‐month and 24‐month groups
Number of subjects: 23
Study 9805101 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g for 5 days, then 3 g daily)
Number of subjects: 32
Study 9805101 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (3 sets of 8 repetitions at 80% of one-repetition maximum, 3 days a week)
Number of subjects: 32
Study 9805101 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 32
Study 9805101 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo) with strength training
Number of subjects: 32
Study 7714978 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyestradiol phosphate plus ethinylestradiol (80 mg polyestradiol phosphate by intramuscular injection every 4 weeks plus 50 micrograms ethinylestradiol 3 times daily)
Number of subjects: 285
Study 7714978 — intervention group
Group type: EXPERIMENTAL
Intervention: Estramustine phosphate (280 mg 2 times daily)
Number of subjects: 285
Study 7714978 — intervention group
Group type: COMPARATOR
Intervention: Deferred treatment (surveillance only)
Number of subjects: 285
Study 3511382 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 29
Study 3511382 — intervention group
Group type: COMPARATOR
Intervention: Sham exchange
Number of subjects: 29
Study 27789050 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intervention group (GIT)
Number of subjects: 4236
Study 27789050 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial intervention group (GIP)
Number of subjects: 4236
Study 27789050 — intervention group
Group type: COMPARATOR
Intervention: Blinded control group (GC)
Number of subjects: 4236
Study 26945929 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide and albuterol delivered via the Combivent Respimat Soft Mist Inhaler (CVT-R)
Number of subjects: 0
Study 26945929 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide alone
Number of subjects: 0
Study 26945929 — intervention group
Group type: COMPARATOR
Intervention: Chlorofluorocarbon-propelled Combivent metered-dose inhaler (CVT-MDI)
Number of subjects: 0
Study 24300131 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical fat-filling procedure (SFFP)
Number of subjects: 100
Study 24300131 — intervention group
Group type: COMPARATOR
Intervention: Non-filling group (control)
Number of subjects: 100
Study 22227638 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 units oxytocin
Number of subjects: 1798
Study 22227638 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 units oxytocin
Number of subjects: 1798
Study 22227638 — intervention group
Group type: COMPARATOR
Intervention: 10 units oxytocin (control)
Number of subjects: 1798
Study 20649032 — intervention group
Group type: EXPERIMENTAL
Intervention: Glargine plus metformin
Number of subjects: 60
Study 20649032 — intervention group
Group type: COMPARATOR
Intervention: Neutral protamine Hagedorn plus metformin
Number of subjects: 60
Study 20649032 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 18517112 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg kg(‐1)) and Remifentanil (0.1 microg kg(‐1) min(‐1))
Number of subjects: 120
Study 18517112 — intervention group
Group type: COMPARATOR
Intervention: Halothane (1%) and Fentanyl (1.5 microg kg(‐1))
Number of subjects: 120
Study 18377139 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid blockade (8 mg naloxone i.v.)
Number of subjects: 125
Study 18377139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 15026911 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use disposable laparoscopic instruments (DLI)
Number of subjects: 125
Study 15026911 — intervention group
Group type: COMPARATOR
Intervention: Reused disposable laparoscopic instruments (DLI) after high-level disinfection
Number of subjects: 125
Study 15026911 — intervention group
Group type: COMPARATOR
Intervention: Single-use DLI
Number of subjects: 125
Study 15026911 — intervention group
Group type: EXPERIMENTAL
Intervention: Reused DLI
Number of subjects: 125
Study 11414007 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention directed to the local level (more difficult selection)
Number of subjects: 0
Study 11414007 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention directed to the global level (less difficult selection)
Number of subjects: 0
Study 11414007 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter presentations of prime and probe
Number of subjects: 0
Study 11414007 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer presentations of prime and probe
Number of subjects: 0
Study 9291757 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2 micrograms.kg‐1
Number of subjects: 50
Study 9291757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 8368544 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% hyperbaric lidocaine
Number of subjects: 56
Study 8368544 — intervention group
Group type: COMPARATOR
Intervention: 5% hyperbaric lidocaine
Number of subjects: 56
Study 2873107 — intervention group
Group type: EXPERIMENTAL
Intervention: tritoqualine
Number of subjects: 21
Study 2873107 — intervention group
Group type: COMPARATOR
Intervention: dexchlorpheniramine maleate (DCPM)
Number of subjects: 21
Study 30508316 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab followed by Denosumab
Number of subjects: 7180
Study 30508316 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by Denosumab
Number of subjects: 7180
Study 28830741 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (360mg DHA + 540mg EPA)
Number of subjects: 50
Study 28830741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 26332701 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone‐acetaminophen
Number of subjects: 174
Study 24500080 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions for physical activity (experimental condition)
Number of subjects: 75
Study 24500080 — intervention group
Group type: COMPARATOR
Intervention: Implementation intentions for an unrelated behavior (control condition)
Number of subjects: 75
Study 24500080 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control condition)
Number of subjects: 75
Study 22151836 — intervention group
Group type: EXPERIMENTAL
Intervention: Mealtime insulin aspart
Number of subjects: 78
Study 22151836 — intervention group
Group type: COMPARATOR
Intervention: Bedtime neutral protamine Hagedorn (NPH) insulin
Number of subjects: 78
Study 20642551 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride (HCl)
Number of subjects: 189
Study 17960950 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised controlled trial (RCT) design
Number of subjects: 0
Study 17960950 — intervention group
Group type: COMPARATOR
Intervention: Retrospective study design
Number of subjects: 0
Study 15595588 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg kg(‐1) alfentanil intravenously
Number of subjects: 82
Study 15595588 — intervention group
Group type: COMPARATOR
Intervention: Peripheral nerve blockade using 1 mLkg(‐1) ropivacaine 0.475%
Number of subjects: 82
Study 15595588 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 microg kg(‐1) alfentanil intravenously with peripheral nerve blockade
Number of subjects: 82
Study 11594440 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline (1 g/day)
Number of subjects: 8
Study 11594440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9520588 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 1035
Study 9520588 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic oestrogen
Number of subjects: 1035
Study 9520588 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen for urogenital disorders
Number of subjects: 1035
Study 7990717 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal periulcer flow measured by laser Doppler fluxometry (LDF)
Number of subjects: 16
Study 7990717 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating blood volume measured by LDF
Number of subjects: 16
Study 7990717 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood velocity measured by LDF
Number of subjects: 16
Study 7990717 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal Q measured by LDF
Number of subjects: 16
Study 7990717 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal V measured by LDF
Number of subjects: 16
Study 7990717 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal U measured by LDF
Number of subjects: 16
Study 7990717 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal values expressed as a percentage of maximal response for Q, V, and U
Number of subjects: 16
Study 3195780 — intervention group
Group type: EXPERIMENTAL
Intervention: Change of flush solution and pressure monitoring tubing every 24 hours
Number of subjects: 30
Study 3195780 — intervention group
Group type: EXPERIMENTAL
Intervention: Change of flush solution every 24 hours and change of pressure monitoring tubing every 48 hours
Number of subjects: 30
Study 3195780 — intervention group
Group type: EXPERIMENTAL
Intervention: Change of flush solution and pressure monitoring tubing every 48 hours
Number of subjects: 30
Study 30007054 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen spray
Number of subjects: 48
Study 30007054 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 48
Study 30007054 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen-SCTG
Number of subjects: 48
Study 30007054 — intervention group
Group type: COMPARATOR
Intervention: Placebo-SCTG
Number of subjects: 48
Study 28644115 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care supplemented by an individually moulded, lightweight, fibreglass heel cast
Number of subjects: 509
Study 28644115 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 509
Study 25953073 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosphenytoin (FOS) 15 mg/kg phenytoin equivalent (PE) administered intravenously
Number of subjects: 50
Study 25953073 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (PBO) administered intravenously
Number of subjects: 50
Study 25953073 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosphenytoin (FOS)
Number of subjects: 50
Study 25953073 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (PBO)
Number of subjects: 50
Study 24597457 — intervention group
Group type: EXPERIMENTAL
Intervention: Door-in-the-face technique with two different requesters present during the same interaction
Number of subjects: 160
Study 24597457 — intervention group
Group type: COMPARATOR
Intervention: Door-in-the-face technique with two different requesters not present during the same interaction
Number of subjects: 160
Study 21586792 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin catheter for hysterosalpingography (HSG)
Number of subjects: 89
Study 21586792 — intervention group
Group type: COMPARATOR
Intervention: Standard metal cannula for hysterosalpingography (HSG)
Number of subjects: 89